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Abstract  
Background: Recent evidence has shown improvements in schizophrenia symptoms after the infusion of sodium nitroprusside (SNP), a nitric oxide (NO) 
donor. In the rat model of schizophrenia using ketamine injection, pretreatment with SNP seems to prevent behavioral changes associated with positive 
symptoms for up to one week. Objective: We investigated whether SNP would have preventative effects on psychogenic symptoms induced by ketamine in 
healthy subjects. Methods: Healthy subjects (N = 38) were assigned to distinct groups that received SNP in different doses (0.15, 0.25, and 0.5 mcg/kg/min). 
First, participants received an infusion of SNP or placebo over 75 minutes. After 10 minutes, they were injected for 1 minute with a bolus of 0.26 mg/kg of 
ketamine and a maintenance dose was started 5 minutes later, with 0.25 mg/kg/h of ketamine for 50 minutes. Results: Ketamine-induced psychopathological 
alterations induced were reduced by SNP, as assessed with the Brief Psychological Rating Scale. Scores in the objective subscale of the Clinician-Administered 
Dissociative States Scale were also lower in SNP sessions compared to placebo. SNP had protective effects against deterioration in facial emotion and identity 
recognition tasks induced by ketamine. Discussion: Our findings support the view that SNP has preventative properties against psychotic manifestations.  
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Introduction
Schizophrenia treatment remains a major challenge for psychiatry1,2, 
since currently available antipsychotics are mostly able to counteract 
positive symptoms such as hallucinations and delusions, but seem 
virtually useless against negative symptoms and cognitive decline. 
This has led researchers to search for alternatives and look into new 
neurotransmitter systems and psychopathological mechanisms that 
could be involved in the manifestations of schizophrenia.
One of these new targets of investigation is the glutamate system. 
Phencyclidine (PCP) and ketamine are widely used in animal 
models of schizophrenia, and both drugs act by blocking the action 
of glutamate on N-methyl-D-aspartate (NMDA) receptors3,4. These 
receptors mediate the production of neuronal nitric oxide (NO) 
and, therefore, the hypothesis was raised that schizophrenia could 
be related to decreased levels of NO in the brain.
To test this hypothesis, researchers pretreated rats with sodium 
nitroprusside (SNP), an NO donor, before injecting them with 
ketamine, which typically induces psychotic-like symptoms. They 
reported that pretreatment with SNP prevented behavioral changes 
in the animals that are commonly associated with positive symptoms 
in humans, such as hyperactivity and stereotypy, and that this effect 
lasted for up to one week3,5.
Based on the results of animal studies and on the fact that SNP 
is a safe drug long used for the management of hypertension, clinical 
investigators decided to test the effects of the drug in schizophrenia 
patients. Hallak et al.6 and Maia-de-Oliveira et al.7,8 described rapid 
improvements in psychotic symptoms and cognitive measures after 
a single, acute infusion of SNP. Using the same design as Hallak et 
al.6, Stone et al.9 failed to find the same improvements, explaining 
that the divergent findings could result from differences in the 
clinical characteristics of the two samples, mainly length of illness 
and symptom exacerbation.
In order to further investigate the connection between 
glutamate, NO and schizophrenia, we conducted a double-blind, 
placebo-controlled trial to test whether the administration of SNP 
could prevent schizophrenia-like symptoms induced by ketamine 
in humans, and whether different doses of SNP would present 
differences in effectiveness and safety.
Methods
Subjects
The sample consisted of 38 healthy volunteers aged 18-45 years. The 
minimum education required was complete high school. Volunteers 
were recruited by advertisement in public areas. Exclusion criteria 
were the presence of clinical diseases or psychiatric disorders, history 
of hypersensitivity to ketamine or SNP, diagnosis of substance abuse 
or dependence, history of professional help-seeking for emotional 
difficulties, psychiatric disorders in first-degree relatives, clinically 
significant psychosocial stress and a positive pregnancy test.
Drugs
The experimental substances used were: (i) SNP (Nipride®, Biolab 
Sanus) in lyophilized powder, dissolved in physiological saline 
solution, and administered by intravenous infusion, in three 
different doses (0.125; 0.25 and 0.5 mcg/kg/min); (ii) ketamine ((S)-
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ketamine – Ketalar®), dissolved in saline solution, and administered 
by intravenous infusion (0.26 mg/kg in bolus followed by 0.25 mg/
kg/h); and (iii) placebo, which consisted of saline solution infused 
according to the same procedures as SNP. 
Assessments
General psychopathology was assessed using the Brazilian Portuguese 
version of the Brief Psychiatric Rating Scale (BPRS)10 and dissociative 
symptoms were quantified using the Clinician-Administered 
Dissociative States Scale (CADSS)11. 
The basic cognitive domains investigated included attention, 
working memory, and verbal fluency, respectively assessed using the 
Stroop Color Word Test (SCWT)12, N-Back, and FAS. Facial affect 
processing, a component of social cognition, was assessed using a 
computerized facial emotional expression and identity matching task. 
Procedure
The study was approved by the Research Ethics Committee of the 
Ribeirão Preto Medical School University Hospital and volunteers 
were informed about the characteristics and implications of the study 
and provided their signed consent to participate.  
The subjects were assessed with screening interviews in the 
first meeting and two experimental sessions were performed within 
the following month with an interval of at least one week between 
sessions. They were instructed to remain abstinent from psychoactive 
substances for at least four weeks prior to the sessions.
In each session, volunteers were injected with ketamine and 
SNP or placebo. The 38 volunteers were randomly assigned to 
the three groups that received different doses of SNP (SNP-0125: 
n = 16; SNP-0250: n = 11; SNP-0500: n = 11). As they arrived 
at the Laboratory of Psychopharmacology, the first sequence 
of rating scales was completed. After vital signs were checked, 
the intravenous infusion of placebo or SNP was initiated and 
maintained for 75 minutes. 
The BPRS was applied immediately after the beginning of the 
infusion. Ten minutes after the continuous infusion of placebo or 
SNP had been initiated in one of the subject’s arms, a bolus injection 
of ketamine (0.26 mg/kg) was infused in the other arm over one 
minute. Ketamine was allowed to distribute for five minutes and 
then a maintenance dose of 0.25 mg/kg/h was administered for 
50 minutes through an infusion pump. During the infusion of the 
experimental drugs, blood pressure was checked every five minutes, 
and heart rate and arterial oxygen saturation were continuously 
monitored. Shortly after the bolus infusion of ketamine, the BPRS 
and CADSS were applied and 15 minutes after the continuous 
infusion of ketamine was initiated, all tests proposed for the study 
were completed. At the end of the procedure, the CADSS and BPRS 
were completed once again. 
Statistical analysis 
The results were analyzed using repeated measures analyses of 
variance (rmANOVA) with drug (SNP and placebo), phase, 
and treatment group (SNP-0125, SNP-0250, and SNP-0500) as 
factors, followed by paired t-tests when indicated. Demographic 
characteristics were analyzed using analysis of variance for 
continuous variables (age and weight) and the chi-square test (c2) 
for the nominal variables gender and education. The physiological 
measures (maximum and minimum blood pressure and heart rate) 
were analyzed considering four measurements performed for each 
item (baseline, five minutes after the infusion of SNP or placebo, five 
minutes after the ketamine bolus and at the end of the experiment), 
with rmANOVA followed by paired t-tests when drug effects or drug-
phase interactions were observed. All statistical tests were performed 
with SPSS software version 17.0.
Results
There were no differences across the groups regarding age, sex, weight 
and education (c2 = 0.41; df = 2; p = 0.82).
Overall, the tolerability, side effects, and effects on physiological 
parameters during the sessions were good. All subjects tolerated both 
experimental sessions well. The most common side effect reported 
was nausea, particularly at the end of the experiment, which was 
already expected since it is relatively common after the administration 
of ketamine13. 
Regarding the physiological measures (systolic blood pressure 
[SBP], diastolic blood pressure [DBP], and heart rate [HR]), the 
rmANOVA showed phase effects on SBP (F3-96 = 121.18; p < 0.01), 
DBP (F3-96 = 157.23; p < 0.01) and HR (F3-96 = 34.99; p < 0.01). Drug 
effects were found on SBP (F1-32 = 4.14; p = 0.05) and DBP (F1-32 = 
4.65; p = 0.04), but not on HR (F1-32 = 0.02, p = 0.96) with the infusion 
of SNP, which resulted in lower values compared to the placebo 
session. There were no interactions between drug and phase in any 
of the physiological measures and no evidence of dose-related effects 
of SNP either. 
The analysis of BPRS total scores showed effects of phase (F4-128 
= 273.24, p < 0.01), drug (F1-32 = 6.38, p = 0.02), and interaction 
between drug and phase (F4-128 = 4.33, p < 0.01), with the group 
that received SNP showing lower psychopathology scores in the 
evaluation following the ketamine bolus (t = 2.27, df = 34, p = 0.03) 
and in the final assessment (t = 2.48, df = 34, p = 0.02), compared to 
the placebo session (Figure 1). 
SNP: sodium nitroprusside; PLB: placebo; Post bolus: evaluation after bolus administration of 
ketamine; Post infusion: measure after 40 minutes of ketamine infusion. Final: measure after 
volunteer recovery phase. * p < 0.05.
Figure 1. Total BPRS scores in different time points.
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There were no detectable effects of specific doses of SNP doses 
(F2-32 = 1.90, p = 0.17). Regarding the BPRS subscales in the post 
bolus phase, scores in the SNP sessions were lower than those in the 
placebo session, showing statistically significant differences for the 
subscales anxiety-depression (t = 2.02, df = 34, p = 0.05), thought 
disorder (t = 2.46, df = 34, p = 0.02) and activation (t = 2.02, df = 34, 
p = 0.05), with a tendency to a significant difference between SNP 
and placebo in the emotional withdrawal subscale (t = 1.96, df = 34, 
p = 0.06) (Figure 2). 
The CADSS is formed by two subscales, with subjective and 
objective items. With respect to the subjective items, rmANOVA 
showed an effect of phase (F2-64 = 268.6, p < 0.01), but no significant 
differences were observed for drug (F1-32 = 2.69, p = 0.11), interaction 
between drug and phase (F2-64 = 1.76, p = 0.18) or SNP dose (F1-32 = 
0.23, p = 0.79). The analysis of the scores in the objective items showed 
effects of phase, drug, and interaction between drug and phase. The 
group taking SNP presented lower general scores and lesser score 
variations in the post bolus evaluation when compared to baseline 
(Figure 3). There was no evidence of effect of the dose of SNP.
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SNP: sodium nitroprusside; PLB: placebo; ANX-DEP: anxiety-depression subscale; WD-RET: 
withdrawal-retardation subscale; THD: thought disorder subscale; ACT: activation subscale. 
* p < 0.05.
Figure 2. Scores in the subscales of the BPRS after injection of the keta-
mine bolus.
SNP: sodium nitroprusside; PLB: placebo; Post bolus: evaluation after bolus administration of 
ketamine; Final: measured after volunteer recovery phase. * p < 0.05.
Figure 3. Scores in the objective items of the CADSS at different time points.
The analysis of the performance in the Stroop Color Word Test 
showed only an effect of phase regarding the time spent for the 
execution of the task (F1-32 = 3.78, p = 0.05) and number of mistakes 
(F1-32 = 26.84, p < 0.01), in both charts 1 and 2 (time: F1-32 = 17.93, 
p < 0.01; number of mistakes: F1-32 = 17.42, p < 0.01). However, no 
effects of drug, SNP dose, or interaction between drug and phase 
were observed. Similarly, the analysis of the performance in the 
N-back also showed an effect of phase (F1-32 = 31.51, p < 0.01), but 
no significant effects of drug (F1-32 = 0.46; p = 0.5), SNP dose (F2-32 
= 0.210, p = 0.9) or interaction between drug and phase (F2-32 = 0.7, 
p = 0.51). The results in the FAS showed no differences with respect 
to letters F and A. Effects of phase (F1-32 = 6.37, p = 0.02) and drug 
(F1-32 = 10.6, p < 0.01) were found in regard to letter S, with a better 
performance of the group that was treated with SNP. However, no 
dose (F2-32 = 0.06, p = 0.95) or interaction (F1-32 = 1.16, p = 0.29) 
effects were observed.
The analysis of emotion recognition data showed effects of phase 
(F1-32 = 29.78, p < 0.01), drug (F1-32 = 4.92, p = 0.03) and interaction 
between phase and drug (F1-32 = 5.78, p = 0.02), but no effect of SNP 
dose (F2-32 = 0.92, p = 0.41) regarding the number of mistakes. The 
t-test showed that the SNP group made fewer mistakes in these tasks 
(t = 3.32, df = 32, p < 0.01) (Figure 4). 
Regarding the time for matching emotions, only effects of phase 
were observed (F1-32 = 4.94, p = 0.03). There were no effects of drug 
(F1-32 = 0.01, p = 0.99), interaction between drug and phase (F1-32 = 
0.96, p = 0.33) or dose (F2-32 = 1.83, p = 0.19). As for the number of 
mistakes in the identity matching task, no effects were found for 
phase (F1-32 = 2.40, p = 0.13) or dose (F2-32 = 0.95, p = 0.4), but there 
were significant effects of drug (F1-32 = 4.71, p = 0.04) and interaction 
between phase and drug (F1-32 = 4.18, p = 0.05), with fewer mistakes 
in the SNP group (t = 2.36, df = 32, p = 0.03) (Figure 5). The analysis 
of the mean time for matching facial identities revealed no significant 
difference between groups. In shape matching, no differences between 
groups were found with regard to time or number of mistakes. In the 
color matching task, an effect of phase was observed in matching time 
(F1-32 = 11.80, p < 0.01), but no effects were observed for drug, dose 
or interaction between drug and phase. The control tasks showed 
differences only in the number of mistakes in color matching, with 
fewer mistakes in the SNP group (Figure 6).
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Figure 4. Number of mistakes in the emotion matching task.
SNP: sodium nitroprusside; PLB: placebo; Final: final measure. * p < 0.05.
Figure 5. Number of mistakes in the identity matching task.
SNP: sodium nitroprusside; PLB: placebo; Final: final measure. * p < 0.05.
Figure 6. Number of mistakes in the tasks of shape and color matching.
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Discussion
To our knowledge, this was the first study to test the effects of SNP 
in healthy human volunteers injected with ketamine. As expected, 
blood pressure was increased immediately after the intravenous bolus 
infusion of ketamine during the placebo session, returning to normal 
levels near the end of the session, which indicates a transient increase 
that did not reach dangerous levels in any of the volunteers. The same 
was observed in respect to heart rate. These findings strengthen the 
cardiovascular safety of the administration of ketamine14. 
During the session with SNP, lower values of SBP and DBP were 
observed after the bolus of ketamine, as well as a faster recovery from 
the transient increase in blood pressure compared with the placebo 
session. These results were also expected since SNP has been used as a 
hypotensive agent in episodes of severe hypertension15. It is important 
to highlight that there were no significant changes in the physiological 
parameters for the different doses of SNP used. One possibility to 
explain this lack of difference among the SNP doses is that all three doses 
(0.125, 0.25, and 0.5 mcg/kg/min) were actually low compared to the 
dose required for SNP to achieve its hypotensive effect (the usual dose 
to treat hypertension is about 0.5-10 mcg/kg/min). Another possibility 
to explain this phenomenon is that individuals with no history of 
hypertension are more resistant to the hypotensive effects of SNP16.
The psychotic-like manifestations induced by ketamine and 
evaluated with the BPRS were significantly lower during the 
administration of SNP when compared to placebo. This difference 
was observed both in the post bolus phase, indicating a lower 
induction of psychopathological symptoms in the acute phase, and 
in the final phase, suggesting a protective effect of SNP. When the 
scores of the BPRS subscales were analyzed separately, a reduction 
in the onset of symptoms induced by ketamine appeared in all four 
BPRS subscales in the SNP group, with significantly lower scores 
compared to placebo in the anxiety-depression, thought disorder and 
activation subscales, and with a tendency to significant reduction in 
the scores of the emotional withdrawal subscale.
The analysis of the objective items of the CADSS showed 
significantly decreased scores in the sessions with SNP compared 
with placebo. Although volunteers were unable to identify in which 
of the sessions they had received SNP, the clinical protection was 
significantly noticeable in these sessions. However, subjects did 
not recognize and did not identify this protection, which can be 
confirmed by the similar results on CADSS subjective scores between 
SNP and placebo sessions. This inability to identify clinical protection 
when under the effect of SNP may be attributed to the dissociative 
and amnestic effects induced by ketamine, which could have impaired 
the subjects’ capacity for self-assessment. 
In the Stroop test, a slightly faster reading pattern in sessions 
with SNP compared to placebo was found, but no statistical 
significance was reached. Neither the N-back nor the FAS scores 
presented significant differences between the SNP and placebo 
sessions. An interesting phenomenon was observed in the N-back 
test that suggests the possibility of a learning effect, since all the 
subjects showed an improvement in task performance in the second 
evaluation when compared to the first evaluation. 
Although the Stroop, N-Back and FAS showed no evidence of 
enhanced cognitive performance in subjects treated with SNP, tests 
that evaluate social cognition (computerized tasks for matching 
emotional expression and facial identity) did provide evidence of a 
better performance compared to the placebo group. Subjects using 
placebo made more mistakes than those taking SNP, suggesting 
that SNP was able to attenuate the impairment in social cognition 
induced by ketamine. Interestingly, these tests were not presented 
in the same way from one session to another, as the Stroop, N-Back 
and FAS were. For each session, there was a new random sequence 
of the same stimuli, which made the possibility of a learning effect 
unlikely. Regarding the control tasks (matching shapes and colors), 
a change in scores among groups was not expected since these are 
tasks of low complexity. However, a significant difference in scores 
between the groups was found in color matching. Volunteers who 
received SNP performed better when compared with volunteers 
who received placebo.
The precise mechanisms through which SNP may produce 
its antipsychotic effects are not completely understood. The most 
likely hypothesis to explain these findings seems to be related to 
SNP’s ability to activate the NO pathway in the NMDA receptor. 
If the symptoms induced by ketamine are due to NMDA receptor 
antagonism, and consequently to an inhibition of NO production 
by nNOS, SNP would probably correct this dysfunction through its 
capacity to increase NO levels. Perhaps the ability of NO to modulate 
cascades of protein kinases, transcription factors, and other gene 
products means that its cascading effects last even when SNP is no 
longer directly active. There is also evidence that NO acts directly 
on NMDA receptors17, which may correct an NMDA receptor 
dysfunction, and that NO also leads to an inhibition of dopamine 
transporters, which may counteract dopamine hypoactivity in the 
prefrontal cortex and, through feedback loops, fix a hyperactivity of 
dopamine in the accumbens and striatum, both abnormalities often 
found in individuals with schizophrenia18. 
Interestingly, we have recently found that the administration 
of SNP produced a break in the pattern of the sleep-wake cycle in 
mice treated with ketamine that was similar to that found in animals 
depleted of dopamine19. Bujas-Bobanovic et al.4 described that SNP 
was able to inhibit the schizophrenia-like behavior and brain c-fos 
expression in rats induced by PCP, an NMDA receptor antagonist. 
Also, Issy et al.20 reported that SNP attenuated the schizophrenia-like 
changes in prepulse inhibition in rats induced by amphetamine, a 
dopaminergic agonist. 
The small sample size is a limitation of this study. Further work 
with larger numbers of participants is necessary. Also, to avoid 
adverse effects resulting from the formation of cyanide or thiocyanate 
which may occur when doses higher than 5 mcg/kg/min of SNP are 
used, typically for a period greater than 24 hours21, SNP was used in 
this study in minimal doses (0.125; 0.25 and 0.5 mcg/kg/min), for a 
short period (75 minutes), and in a single infusion. The three doses 
of SNP showed no significant differences in any of the parameters 
evaluated. Future experiments should examine the effects and safety 
of higher doses and multiple infusions of SNP. 
Since the schizophrenia-like syndrome induced by NMDA receptor 
antagonists is now a frequently used pharmacological model for studying 
schizophrenia, these findings give support to the hypothesis that NO 
donors such as SNP may have beneficial effects for schizophrenia 
patients22-25. Several studies have shown that the prevention of psychotic 
relapse has major implications for the minimization of damage and of 
some disabilities that typically affect patients with schizophrenia26,27, 
and the results described here suggest that SNP may represent a new 
approach for the management of the disorder. 
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